Kiniksa Pharmaceuticals (KNSA) News Today → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free KNSA Stock Alerts $20.19 -0.07 (-0.35%) (As of 05/9/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineKiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conferenceglobenewswire.com - May 7 at 4:01 PMKiniksa Pharmaceuticals (NASDAQ:KNSA) Coverage Initiated by Analysts at Wells Fargo & Companyamericanbankingnews.com - May 7 at 6:22 AMJPMorgan Chase & Co. Boosts Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target to $30.00americanbankingnews.com - May 4 at 6:16 AMWells Fargo Initiates Coverage of Kiniksa Pharmaceuticals (KNSA) with Overweight Recommendationmsn.com - May 4 at 6:14 AMKiniksa Pharmaceuticals (NASDAQ:KNSA) Coverage Initiated at Wells Fargo & Companymarketbeat.com - May 3 at 6:25 PMKiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $30.00 at JPMorgan Chase & Co.marketbeat.com - May 1 at 11:45 AMAnalyst Estimates: Here's What Brokers Think Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) After Its First-Quarter Reportfinance.yahoo.com - April 26 at 9:01 AMKiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call Transcriptseekingalpha.com - April 25 at 7:58 AMKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Forecasted to Post Q2 2024 Earnings of ($0.06) Per Sharemarketbeat.com - April 25 at 7:52 AMBuy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug Prospectsmarkets.businessinsider.com - April 24 at 4:56 PMCan Growing Adoption Of Arcalyst Drive KNSA Stock Up?markets.businessinsider.com - April 24 at 4:56 PMKiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shapeseekingalpha.com - April 24 at 4:56 PMKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcriptfinance.yahoo.com - April 24 at 4:56 PMKiniksa Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - April 24 at 4:56 PMEvercore ISI Boosts Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target to $30.00marketbeat.com - April 24 at 2:54 PMKiniksa Pharmaceuticals (NASDAQ:KNSA) Announces Quarterly Earnings Results, Misses Estimates By $0.11 EPSmarketbeat.com - April 24 at 9:45 AMBuy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial Executionmarkets.businessinsider.com - April 24 at 3:19 AMKiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Outperform Rating from Wedbushmarketbeat.com - April 23 at 1:49 PMKiniksa Pharmaceuticals, Ltd. 2024 Q1 - Results - Earnings Call Presentationseekingalpha.com - April 23 at 1:03 PMKiniksa Pharmaceuticals reports mixed Q1 results; raises FY24 outlookmsn.com - April 23 at 12:18 PMKNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024markets.businessinsider.com - April 23 at 12:18 PMKiniksa Pharmaceuticals Ltd (KNSA) Q1 2024 Earnings Overview: Surpasses Revenue Forecastsfinance.yahoo.com - April 23 at 12:18 PMKiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Executionglobenewswire.com - April 23 at 7:30 AMKiniksa Pharmaceuticals Ltd (KNSA)investing.com - April 20 at 9:06 PMKiniksa Pharmaceuticals (KNSA) Scheduled to Post Quarterly Earnings on Tuesdaymarketbeat.com - April 17 at 6:59 PMKiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024globenewswire.com - April 16 at 4:01 PMVanguard Group Inc. Sells 128,255 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)marketbeat.com - April 9 at 4:08 AMWedbush Research Analysts Reduce Earnings Estimates for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)marketbeat.com - April 5 at 8:36 AMFY2027 EPS Estimates for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Reduced by Wedbushmarketbeat.com - April 4 at 9:45 AMKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Down 3.6% marketbeat.com - April 3 at 1:57 PMKiniksa Pharmaceuticals (NASDAQ:KNSA) Earns "Outperform" Rating from Wedbushmarketbeat.com - April 2 at 11:12 PMKiniksa Pharmaceuticals Announces Development Indication for Abiprubartglobenewswire.com - April 2 at 7:30 AMInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sells 5,582 Shares of Stockinsidertrades.com - March 16 at 10:15 AMKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Holdings Lowered by Hudson Bay Capital Management LPmarketbeat.com - March 15 at 6:57 AMKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by AQR Capital Management LLCmarketbeat.com - March 12 at 5:28 AM5 Biotech Stocks With 26% Upside Potential or Moremsn.com - March 7 at 10:02 PMSchonfeld Strategic Advisors LLC Buys 134,070 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)marketbeat.com - March 6 at 6:52 AMKiniksa Pharmaceuticals (NASDAQ:KNSA) Hits New 12-Month High at $22.09marketbeat.com - March 4 at 10:52 AMEarnings call: Kiniksa Pharmaceuticals sees robust growth in ARCALYST salesinvesting.com - March 3 at 12:32 AMKiniksa Pharmaceuticals Ltd.wsj.com - March 3 at 12:32 AMKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna Sells 5,126 Sharesmarketbeat.com - March 1 at 7:12 PMKiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 1 at 8:23 AMKiniksa Pharmaceuticals Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - March 1 at 8:23 AMQ1 2024 EPS Estimates for Kiniksa Pharmaceuticals, Ltd. Boosted by Analyst (NASDAQ:KNSA)marketbeat.com - March 1 at 7:26 AMChief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)finance.yahoo.com - March 1 at 1:35 AMAre You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choicefinance.yahoo.com - February 29 at 3:16 PMKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 29 at 10:15 AMWedbush Weighs in on Kiniksa Pharmaceuticals, Ltd.'s Q1 2025 Earnings (NASDAQ:KNSA)marketbeat.com - February 29 at 8:53 AMAnalysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA)markets.businessinsider.com - February 28 at 7:01 PMKiniksa Pharmaceuticals Ltd (KNSA) Reports Strong Revenue Growth in Q4 and Full-Year 2023finance.yahoo.com - February 28 at 9:00 AM Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address “Crash Insurance” For Your Retirement (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. KNSA Media Mentions By Week KNSA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KNSA News Sentiment▼0.470.43▲Average Medical News Sentiment KNSA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KNSA Articles This Week▼62▲KNSA Articles Average Week Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Gyre Therapeutics News Xencor News Morphic News Akero Therapeutics News Arcus Biosciences News ANI Pharmaceuticals News Verona Pharma News Ligand Pharmaceuticals News Gemini Therapeutics News Pacira BioSciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KNSA) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
